24/7 Market News Snapshot 24 June, 2025 – Immunic, Inc. Common Stock (NASDAQ:IMUX)

June 24, 2025

DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:IMUX) are discussed in this article.
Immunic, Inc. (IMUX) is witnessing a significant surge in market activity, with shares trading at $0.759, reflecting a robust increase of 7.20% from the previous day’s close of $0.708. This uptick is supported by substantial trading volume, exceeding 6.85 million shares, signaling considerable investor interest and a positive market sentiment surrounding the company’s future. Analysts recommend that investors keep a close watch on key technical indicators, such as moving averages and the relative strength index (RSI), to identify support and resistance levels that could impact potential price movements.

In conjunction with this market momentum, Immunic has recently released promising long-term data from its Phase 2 EMPhASIS trial regarding its lead asset, vidofludimus calcium, aimed at treating relapsing-remitting multiple sclerosis (RRMS). The oral therapy demonstrated substantial efficacy, with 92.3% of participants remaining free of 12-week confirmed disability worsening (CDW) at Week 144, and 92.7% maintaining this status at the 24-week mark. The open-label extension (OLE) trial yielded approximately 952 treatment years of data, reinforcing the treatment’s potential.

Critically, the findings revealed that nearly half of the confirmed CDW events were tied to relapse-associated worsening, while a smaller fraction was linked to progression independent of relapse activity. Notably, vidofludimus calcium maintained a strong safety and tolerability profile, as evidenced by low discontinuation rates and no emergence of new safety concerns during treatment periods spanning up to 5.5 years.

Dr. Daniel Vitt, CEO of Immunic, emphasized the importance of the results in addressing a significant unmet need in multiple sclerosis management, particularly in delaying disability progression. The innovative therapy, characterized by its dual mode of action—combining neuroprotection and anti-inflammatory effects—positions Immunic for a forward-thinking approach in the treatment of chronic inflammatory diseases. As the company prepares for Phase 3 trials, expectations are set high for vidofludimus calcium to enhance the quality of life for individuals living with multiple sclerosis.

Related news for (IMUX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.